In many cancer research centers, the causes, diagnosis, and
treatment of the disease are investigated. Scientists, such Doug Rosenthal are getting a
little better understanding of how changes in a person's DNA can cause normal
cells to become cancerous. A better understanding of the genetic changes that
can occur in cancer offers some clues as to why these cells become abnormal.
Some of these advances may lead to better diagnoses and treatments for cancer
of unknown primary origin.
Diagnosis
It is important that doctors can identify the origin of
cancers of unknown primary origin, so that the most effective treatments can be used. Rosenthal specifies that immuno-histochemistry
and other laboratory tests can be very helpful for this purpose, but these
tests still cannot indicate where all cancers of unknown primary origin have
started. New laboratory tests, and others, which are currently under study, will help to more accurately classify cancer of
unknown primary origin and help predict the patient's prognosis and response to
treatment.
“The
number of cancers of unknown primary origin is expected to drop dramatically at
some point in the future as doctors can test tumor samples and determine
cancers,” says the experienced
scientist, Rosenthal.
Treatment
Cancer of unknown primary origin represents a number of
different types of cancer. So, it is unlikely that a single innovative
treatment will benefit all people with cancer of unknown primary origin. Still,
advances in the treatment of some of the more common cancers are likely to
benefit people with cancer of unknown primary origin as well, especially if the
cancers can be more accurately classified.
As researchers, such as Rosenthal, have come to understand the genetic changes
that these tumors cause, they have been able to use new treatments that target
these changes. Some of these newer medications are called targeted therapies.
These drugs have more selective effects compared to chemotherapy. Some of
these, such as bevacizumab (Avastin) and erlotinib (Tarceva), are available to
treat other cancers and have shown some activity in cancer of unknown primary
origin.
Recent studies done by the scientist with a wide career as a researcher in the field of biology, Rosenthal have found that cancers that start in every
organ are not all the same. These can present different changes in their most
important molecules and respond differently to treatments.
As targeted treatments for more of the specific molecular
changes in cancer cells are discovered, knowing the origin of a cancer may
become less important. Instead, detailed information about changes in the DNA
and RNA of cancer cells may be more important in selecting the treatments that
are most likely to help individual patients.
Rosenthal indicates
that cancer cells from cancer of unknown primary origin are sometimes
tested in a laboratory to try to determine which chemotherapy drugs are likely
to work. Unfortunately, these tests are not always effective in predicting which
chemotherapy drugs are appropriate and which are the most effective. Many
doctors do not find these tests very helpful.
Many patients with cancer of unknown primary origin face a
serious prognosis. Therefore, the need for progress in treatment is obvious.
Clinical studies of new treatments are an essential part if progress is to be
made in this field. Some of these studies are testing new chemotherapy drugs,
new drug combinations, and new ways to administe them. Other studies, such as those made by Doug Rosenthal (contact him through Acuity Scheduling),
focus on new approaches to treatment, such as biologic therapy, immunotherapy,
and gene therapy. Since cancer of unknown primary origin includes many types of
cancer, the progress that is made will most likely depend on continued progress
in understanding the molecular basis of all cancers.
No comments:
Post a Comment